With the Trump administration now openly acknowledging weak U.S. economic data and investors on edge about slowing growth, the hunt for calmer corners of the market has intensified. Periods of rising anxiety and possible policy responses can punish fragile balance sheets and reward resilience. This article walks through three low volatility stocks that appear relatively better placed against this backdrop and explains why each one might deserve a closer look right now.

The stocks covered below are just a small sample, and the full low volatility screen surfaced 32 more companies with similarly detailed stories that are not included here. If you want to go straight to the source and identify, compare, and analyze the ideas that best match your risk profile, head into the Low Volatility Stocks screener.

Boston Scientific (BSX)

Boston Scientific is a large medical device company that makes equipment used in heart procedures, pain management, urology, and other minimally invasive treatments in hospitals around the world. It generates about US$7.1b from its MedSurg segment and roughly US$13.9b from Cardiovascular and Rhythm related products, which means most revenue comes from heart and vascular care. With a market cap of about US$71.5b, Boston Scientific sits firmly in the large cap, established end of the healthcare sector.

Boston Scientific stands out in a choppy macro backdrop because its devices support essential procedures rather than discretionary spending, and the stock has shown relatively low volatility compared with more cyclical areas of the market. The story is not risk free, with debt funding, product recalls and pressure in key franchises like WATCHMAN and Electrophysiology all worth watching closely. At the same time, strong profitability, cost saving plans and a deep pipeline in areas like FARAPULSE highlight that there are multiple factors to consider for this medical device company beyond recent guidance cuts.

Boston Scientific’s essential procedures and low volatility profile are only half the story. The real question is whether the balance of risk and opportunity still stacks up in your favor. Start with the 4 key rewards and 1 important warning sign

Build your own resilient healthcare shortlist

Boston Scientific and the two other low volatility stocks in this piece all came from the same screener, but the real edge is in shaping filters around what matters most to you. Use our flexible Screener to blend valuation, growth, balance sheet and risk filters, or jump straight into any of our curated Investing Ideas.

Aon (AON)

Aon is a global professional services firm that helps companies manage risk, benefits, pensions and capital. It generates about US$11.7b from its Risk Capital segment and roughly US$5.9b from Human Capital, with a small corporate adjustment, so most revenue comes from insurance and risk solutions. With a market cap of about US$76.0b, Aon sits in the large cap end of the global financial services sector.

Aon is built for periods of stress, which is exactly when investors start looking harder at low volatility stocks. The company links its services directly to the four big forces its clients worry about most: trade, technology, weather and workforce. Recent results show broad based 5% organic growth with improving margins and strong free cash flow. At the same time, high leverage, an earnings profile that is not forecast to grow quickly and sensitivity to GDP in more discretionary work mean the story is not without risk. The bigger question for you is whether a resilient, cash generative broker that often benefits when volatility spikes is the kind of ballast you want while the Trump administration is flagging weaker data and investors are bracing for a bumpier ride.

Aon’s steady 5% organic growth and strong free cash flow can mask where the real inflection points sit. Get the full context in the analysis report for Aon

CorVel (CRVL)

CorVel runs technology driven workers’ compensation and medical cost management programs for employers, insurers, and government agencies. It generates all of its roughly US$984 million in revenue from Managed Care services in the United States, and its current market cap is about US$3.2b.

CorVel sits in an interesting spot for investors looking for quieter stocks while the Trump administration is acknowledging softer U.S. data and volatility picks up. Earnings have grown around 14% a year over the past 5 years, profitability has been improving, and the business is debt free with strong return on equity, which can appeal to defensive investors who still want growth. At the same time, the P/E multiple is above the healthcare average, insiders have been selling, and ongoing buybacks concentrate exposure. The real question is whether CorVel’s claims volume growth, AI driven cost control and new leadership are enough to justify paying a premium for that stability story.

CorVel’s earnings growth, clean balance sheet and higher P/E suggest the market sees something durable here. To evaluate how that growth story compares with the price you pay, go straight to the analyst forecasts for CorVel

Seeking Fresh Alternatives Before The Crowd

Markets move fast and the most interesting ideas rarely stay under the radar for long. Spot early breakout potential, catch real momentum while it matters, and get in early.

• Spot resilient dividend payers before yields get compressed by latecomers using the curated 9 dividend fortresses that focus on income strength and balance sheet support.
• Ride the next wave of real-world AI adoption with hand picked 56 AI infrastructure stocks helping power data centers, chips, and the hardware behind the headlines.
• Position for structural demand in electrification and infrastructure using the focused 9 top copper producer stocks that concentrate on established producers, not short lived stories.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.